NCT06759922View on ClinicalTrials.gov

Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes

PHASE4RecruitingINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

March 30, 2025

Study Completion Date

June 30, 2025

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Tab Metformin + Tab Glimepiride

Tab Metformin 500mg+ Tab Glimepiride 2mg (FDC) once per orally for 90 days.

DRUG

Tab Metformin + Tab Empagliflozin

Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) once per orally for 90 days.

DRUG

Tab Metformin +Tab Sitagliptin

Tab Metformin 500mg+Tab Sitagliptin 50mg (FDC) once per orally for 90 days.

DRUG

Tab Metformin + Tab Empagliflozin + Tab Sitagliptin

Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) + Tab Sitagliptin 50mg once per orally for 90 days.

Trial Locations (1)

75500

RECRUITING

National Medical Center, Karachi

All Listed Sponsors
lead

Bahria University

OTHER